Current Treatment Approaches Against Lung Cancer

Worldwide, lung cancer is a major health hazard. Multiple approaches are needed to treat this pathological condition. Tobacco control enforcement must be strengthened. To reduce lung cancer mortality, early detection programs are recommended. The fundamental mechanisms that make this cancer aggressive are less understood. Multiregional sequencing allows intratumor heterogeneity to be used to analyze cancer phylogeny. Compared to malignancies in nonsmokers, the tumors exhibited similar rates of EGFR mutations and oncogenic isoforms of RET, ROS1, ALK, and MET. This suggests these cancers share the same origin and development. Identification of oncogenic driver mutations has considerably improved metastatic non-small cell lung cancer (NSCLC) treatment personalization. Perioperative chemotherapy, which had little benefits, was the only treatment choice for early-stage operable NSCLC patients. In clinical trials, disease-free survival and event-free survival are surrogate endpoints for overall survival, although phase 3 cancer research should employ them.